Encyclopedia of Pathology

Living Edition
| Editors: J.H.J.M. van Krieken

Fibrocystic Breast Changes

  • Isabella Castellano
  • Jasna Metovic
Living reference work entry
DOI: https://doi.org/10.1007/978-3-319-28845-1_4707-1



The term “fibrocystic changes” (FCs) covers a wide variety of clinical and pathological conditions from painful breast to solid lump, multiple cysts, or diffuse nodularity. These abnormalities are noncancerous disorders and do not represent a specific disease but rather a sign of response of the breast tissue to hormone levels in different phases of women life. Since FCs are the most frequent breast abnormalities, the previous definition referred as “fibrocystic breast disease” was abandoned in favor of “fibrocystic breast changes,” as stated in a consensus meeting in New York in 1985 (Hutter et al. 1986). In addition, for some authors this entity may be simply an “aberration of normal development and involution of tissue breast,” in which the diagnostic definition of FCs is more quantitative than qualitative (Tot et al. 2014). However, it is necessary to underline that the term...

This is a preview of subscription content, log in to check access.

Reference and Further Reading

  1. Bartow, S. A., Black, W. C., Waeckerlin, R. W., & Mettler, F. A. (1982). Fibrocystic disease: A continuing enigma. Pathology Annual, 2, 93–111.Google Scholar
  2. Boyd, M., Hildebrandt, R. H., & Bartow, S. A. (1996). Expression of the estrogen receptor gene in developing and adult human breast. Breast Cancer Research and Treatment, 37, 243–251.CrossRefGoogle Scholar
  3. Castells, X., Domingo, L., Corominas, J. M., Torá-Rocamora, I., Quintana, M. J., Baré, M., Vidal, C., Natal, C., Sánchez, M., Saladié, F., Ferrer, J., Vernet, M., Servitja, S., Rodríguez-Arana, A., Roman, M., Espinàs, J. A., & Sala, M. (2015). Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: A study from a population-based screening program. Breast Cancer Research and Treatment, 149, 237–244.CrossRefGoogle Scholar
  4. Celis, J. E., Gromova, I., Gromov, P., Moreira, J. M., Cabezón, T., Friis, E., & Rank, F. (2006). Molecular pathology of breast apocrine carcinomas: A protein expression signature specific for benign apocrine metaplasia. FEBS Letters, 580, 2935–2944.CrossRefGoogle Scholar
  5. Cserni, G. (2012). Benign apocrine papillary lesions of the breast lacking or virtually lacking myoepithelial cells-potential pitfalls in diagnosing malignancy. Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 120, 249–252.CrossRefGoogle Scholar
  6. Dupont, W. D., & Page, D. L. (1985). Risk factors for breast cancer in women with proliferative breast disease. New England Journal of Medicine, 312, 146–151.CrossRefGoogle Scholar
  7. Faiz, O., & Fentiman, I. S. (2000). Management of breast pain. International Journal of Clinical Practice, 54, 228–232.PubMedGoogle Scholar
  8. Gromov, P., Espinoza, J. A., & Gromova, I. (2015). Molecular and diagnostic features of apocrine breast lesions. Expert Review of Molecular Diagnostics, 15, 1011–1022.CrossRefGoogle Scholar
  9. Hartmann, L. C., Sellers, T. A., Frost, M. H., Lingle, W. L., Degnim, A. C., Ghosh, K., Vierkant, R. A., Maloney, S. D., Pankratz, V. S., Hillman, D. W., Suman, V. J., Johnson, J., Blake, C., Tlsty, T., Vachon, C. M., Melton, L. J., 3rd, & Visscher, D. W. (2005). Benign breast disease and the risk of breast cancer. The New England Journal of Medicine, 353, 229–237.CrossRefGoogle Scholar
  10. Hutter, R. V. P., Albores-Saavedra, J., & Anderson, E. et al. (1986). Is ‘fibrocystic disease’ of the breast precancerous? Consensus meeting, New York, October 1985. Archives of Pathology & Laboratory Medicine, 110, 121.Google Scholar
  11. Kabat, G. C., Jones, J. G., Olson, N., Negassa, A., Duggan, C., & Ginsberg, M. (2010). A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes and Control, 21, 821–828.CrossRefGoogle Scholar
  12. Milosevic, Z. C., Nadrljanski, M. M., Milovanovic, Z. M., Gusic, N. Z., Vucicevic, S. S., & Radulovic, O. S. (2017). Breast dynamic contrast enhanced MRI: Fibrocystic changes presenting as a non-mass enhancement mimicking malignancy. Radiology and Oncology, 51, 130–136.PubMedPubMedCentralGoogle Scholar
  13. Mousavi, S. R., Mousavi, S. M., Samsami, M., & Mahdikhah, Z. (2010). Comparison of tamoxifen with danazol in the management of fibrocystic disease. International Journal of Medicine and Medical Sciences, 2, 329–331.Google Scholar
  14. O’Malley, F. P., & Bane, A. (2008). An update on apocrine lesions of the breast. Histopathology, 52, 3–10.CrossRefGoogle Scholar
  15. Page, D. L., Vander Zwaag, R., Rogers, L. W., Williams, L. T., Walker, W. E., & Hartmann, W. H. (1978). Relation between component parts of fibrocystic disease complex and breast cancer. Journal of the National Cancer Institute, 61(4), 1055–1063.PubMedGoogle Scholar
  16. Parrella, P., Poeta, M. L., Gallo, A. P., Prencipe, M., Scintu, M., Apicella, A., Rossiello, R., Liguoro, G., Seripa, D., Gravina, C., Rabitti, C., Rinaldi, M., Nicol, T., Tommasi, S., Paradiso, A., Schittulli, F., Altomare, V., & Fazio, V. M. (2004). Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clinical Cancer Research, 10, 5349–5354.CrossRefGoogle Scholar
  17. Pruthi, S., Wahner-Roedler, D. L., Torkelson, C. J., Cha, S. S., Thicke, L. S., Hazelton, J. H., & Bauer, B. A. (2010). Vitamin E and evening primrose oil for management of cyclical mastalgia: A randomized pilot study. Alternative Medicine Review, 15, 59–67.PubMedGoogle Scholar
  18. Radi, M. J. (1989). Calcium oxalate crystals in breast biopsies. An overlooked form of microcalcification associated with benign breast disease. Archives of Pathology & Laboratory Medicine, 113(12), 1367–1369.Google Scholar
  19. Shaaban, A. M., Sloane, J. P., West, C. R., Moore, F. R., Jarvis, C., & Williams, E. M. I. (2002). Histopathologic types of benign breast lesions and the risk of breast cancer: case-control study. American Journal of Surgical Pathology, 26, 421–430.CrossRefGoogle Scholar
  20. Simard, J., Hatton, A. C., Labrie, C., Dauvois, S., Zhao, H. F., Haagensen, D. E., & Labrie, F. (1989). Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. Molecular Endocrinology, 3, 694–702.CrossRefGoogle Scholar
  21. Smith, R. L., Pruthi, S., & Fitzpatrick, L. A. (2004). Evaluation and management of breast pain. Mayo Clinic Proceedings, 79, 353–372.CrossRefGoogle Scholar
  22. Tavassoli, F. A., & Norris, H. J. (1994). Intraductal apocrine carcinoma: A clinicopathologic study of 37 cases. Modern Pathology, 7, 813–818.PubMedGoogle Scholar
  23. Tot, T., Tabàr, L., & Dean, P. B. (2014). Practical breast pathology. Normal breast tissue or fibrocystic change? (pp. 2–23). Stuttgart: Thieme Publishing Group.Google Scholar
  24. Tramm, T., Kim, J. Y., & Tavassoli, F. A. (2011). Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast. American Journal of Surgical Pathology, 35, 202–211.CrossRefGoogle Scholar
  25. Wang, J., Costantino, J. P., Tan-Chiu, E., Wickerham, D. L., Paik, S., & Wolmark, N. (2004). Lower-category benign breast disease and the risk of invasive breast cancer. Journal of the National Cancer Institute, 96, 616–620.CrossRefGoogle Scholar
  26. Washington, C., Dalbègue, F., Abreo, F., Taubenberger, J. K., & Lichy, J. H. (2000). Loss of heterozygosity in fibrocystic change of the breast: Genetic relationship between benign proliferative lesions and associated carcinomas. American Journal of Pathology, 157, 323–329.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medical SciencesUniversity of TurinTurinItaly
  2. 2.Department of OncologyUniversity of TurinTurinItaly